within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB08_Galsulfase;

model Galsulfase
  extends Pharmacolibrary.Drugs.ATC.A.A16AB08;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A16AB08</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Galsulfase is a recombinant human N-acetylgalactosamine-4-sulfatase enzyme used in enzyme replacement therapy for patients with mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome). It is approved for intravenous use to slow or reverse the accumulation of glycosaminoglycans in affected tissues.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in pediatric and adult patients with MPS VI receiving recommended doses.</p><h4>References</h4><ol><li><p> (2005). Galsulfase: arylsulfatase B, BM 102, recombinant human arylsulfatase B, recombinant human N-acetylgalactosamine-4-sulfatase, rhASB. <i>Drugs in R&amp;D</i> 6(5) 312–315. DOI:<a href=&quot;https://doi.org/10.2165/00126839-200506050-00008&quot;>10.2165/00126839-200506050-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16128602/&quot;>https://pubmed.ncbi.nlm.nih.gov/16128602</a></p></li><li><p>Ruane, T, et al., &amp; O&#x27;Neill, CA (2016). Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations. <i>Molecular genetics and metabolism</i> 117(2) 157–163. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgme.2015.10.006&quot;>10.1016/j.ymgme.2015.10.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26776148/&quot;>https://pubmed.ncbi.nlm.nih.gov/26776148</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Galsulfase;
